CN116507622B - Gpr52调节剂化合物 - Google Patents
Gpr52调节剂化合物Info
- Publication number
- CN116507622B CN116507622B CN202180073276.0A CN202180073276A CN116507622B CN 116507622 B CN116507622 B CN 116507622B CN 202180073276 A CN202180073276 A CN 202180073276A CN 116507622 B CN116507622 B CN 116507622B
- Authority
- CN
- China
- Prior art keywords
- disorder
- tetrahydro
- pyridin
- compound
- trifluoromethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Amplifiers (AREA)
- Optical Modulation, Optical Deflection, Nonlinear Optics, Optical Demodulation, Optical Logic Elements (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2013558.8 | 2020-08-28 | ||
| GBGB2013558.8A GB202013558D0 (en) | 2020-08-28 | 2020-08-28 | GRP52 Modularor compounds |
| PCT/GB2021/052247 WO2022043714A1 (en) | 2020-08-28 | 2021-08-31 | Gpr52 modulator compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116507622A CN116507622A (zh) | 2023-07-28 |
| CN116507622B true CN116507622B (zh) | 2026-02-24 |
Family
ID=72749711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180073276.0A Active CN116507622B (zh) | 2020-08-28 | 2021-08-31 | Gpr52调节剂化合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230348416A1 (https=) |
| EP (1) | EP4204408A1 (https=) |
| JP (1) | JP7761635B6 (https=) |
| KR (1) | KR20230058132A (https=) |
| CN (1) | CN116507622B (https=) |
| AU (1) | AU2021330379A1 (https=) |
| BR (1) | BR112023003696A2 (https=) |
| CA (1) | CA3193487A1 (https=) |
| GB (1) | GB202013558D0 (https=) |
| IL (1) | IL301007B1 (https=) |
| MX (1) | MX2023002389A (https=) |
| WO (1) | WO2022043714A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202206413A (zh) | 2020-04-22 | 2022-02-16 | 美商紐羅克里生物科學有限公司 | Gpr52調節劑及其使用方法 |
| WO2025117662A1 (en) * | 2023-11-29 | 2025-06-05 | Actio Biosciences, Inc. | Heterocyclic compounds useful as kcnt1 inhibitors |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108174603A (zh) * | 2015-04-29 | 2018-06-15 | 阿芮纳制药有限公司 | 作为gpr52调节剂的用于治疗或预防其相关病症的1-杂芳基-二氢吲哚-4-甲酰胺 |
| CN108349947A (zh) * | 2015-11-02 | 2018-07-31 | S·莱恩 | 四氢吲唑及其医药用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021009003A1 (en) * | 2019-07-16 | 2021-01-21 | Universität Hamburg | Computer-based identification of types in the empirical sciences by tangle theory |
| CA3156474A1 (en) * | 2019-11-08 | 2021-05-14 | Heptares Therapeutics Limited | GPR52 MODULATING COMPOUNDS |
-
2020
- 2020-08-28 GB GBGB2013558.8A patent/GB202013558D0/en not_active Ceased
-
2021
- 2021-08-31 US US18/023,411 patent/US20230348416A1/en active Pending
- 2021-08-31 KR KR1020237010457A patent/KR20230058132A/ko active Pending
- 2021-08-31 IL IL301007A patent/IL301007B1/en unknown
- 2021-08-31 WO PCT/GB2021/052247 patent/WO2022043714A1/en not_active Ceased
- 2021-08-31 CN CN202180073276.0A patent/CN116507622B/zh active Active
- 2021-08-31 CA CA3193487A patent/CA3193487A1/en active Pending
- 2021-08-31 AU AU2021330379A patent/AU2021330379A1/en active Pending
- 2021-08-31 EP EP21769501.4A patent/EP4204408A1/en active Pending
- 2021-08-31 MX MX2023002389A patent/MX2023002389A/es unknown
- 2021-08-31 JP JP2023514050A patent/JP7761635B6/ja active Active
- 2021-08-31 BR BR112023003696A patent/BR112023003696A2/pt unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108174603A (zh) * | 2015-04-29 | 2018-06-15 | 阿芮纳制药有限公司 | 作为gpr52调节剂的用于治疗或预防其相关病症的1-杂芳基-二氢吲哚-4-甲酰胺 |
| CN108349947A (zh) * | 2015-11-02 | 2018-07-31 | S·莱恩 | 四氢吲唑及其医药用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7761635B6 (ja) | 2025-11-27 |
| EP4204408A1 (en) | 2023-07-05 |
| WO2022043714A1 (en) | 2022-03-03 |
| JP7761635B2 (ja) | 2025-10-28 |
| CN116507622A (zh) | 2023-07-28 |
| AU2021330379A1 (en) | 2023-03-30 |
| MX2023002389A (es) | 2023-05-03 |
| GB202013558D0 (en) | 2020-10-14 |
| IL301007A (en) | 2023-05-01 |
| KR20230058132A (ko) | 2023-05-02 |
| US20230348416A1 (en) | 2023-11-02 |
| CA3193487A1 (en) | 2022-03-03 |
| JP2023539336A (ja) | 2023-09-13 |
| BR112023003696A2 (pt) | 2023-04-04 |
| IL301007B1 (en) | 2026-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103298809B (zh) | 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途 | |
| US20100292266A1 (en) | Oxazolyl Piperidine Modulators of Fatty Acid Amide Hydrolase | |
| CN115515681B (zh) | Gpr52调节剂化合物 | |
| CA3203285A1 (en) | Heteroaryl carboxamide compound | |
| CA3047404A1 (en) | Compounds, compositions and methods of use | |
| WO2013131018A1 (en) | Biaryl inhibitors of the sodium channel | |
| KR20200014915A (ko) | 디아자비시클릭 치환된 이미다조피리미딘 및 호흡 장애의 치료를 위한 그의 용도 | |
| CN115210233B (zh) | 作为组蛋白脱乙酰酶6抑制剂的1,3,4-噁二唑衍生物化合物以及包含其的药物组合物 | |
| CN117440955A (zh) | 具有食欲素-2受体激动剂活性的取代的酰胺大环化合物 | |
| CN116507622B (zh) | Gpr52调节剂化合物 | |
| JP5635181B2 (ja) | ニトロイミダゾール系化合物、その製造方法および用途 | |
| KR20220098160A (ko) | 아드레날린수용체 adrac2의 억제제 | |
| JP2009514802A (ja) | ナトリウムチャネルモジュレーターとしてのプロリンアミド誘導体 | |
| WO2016121782A1 (ja) | スルホンアミド化合物 | |
| EP4401833B1 (en) | Gpr52 modulator compounds | |
| CN115515943A (zh) | 噁二唑衍生物 | |
| EP2524912A1 (en) | Amine derivatives | |
| EP3980401B1 (en) | Purine derivatives, as nr2b negative modulators and the use thereof as medicament, in particular for treating depressive disorders | |
| RS61886B1 (sr) | Fluoropiperidinska jedinjenja kao čisti antagonisti 5-ht6 receptora | |
| HK40107480B (en) | Gpr52 modulator compounds | |
| HK40107480A (en) | Gpr52 modulator compounds | |
| CN115784986A (zh) | 一种hdac6抑制剂及其制备方法和应用 | |
| EA040294B1 (ru) | Фторопиперидиновые соединения в качестве чистых антагонистов 5-ht6-рецептора | |
| HK40023760B (zh) | 磺酰胺化合物及其用途 | |
| HK1196604A1 (zh) | 氟化的芳基烷基氨基甲酰胺衍生物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Country or region after: Britain Address after: Britain Applicant after: Nexla Pharmaceuticals UK Ltd. Address before: Cambridge County, England Applicant before: Hepares Treatment Co.,Ltd. Country or region before: Britain |
|
| CB02 | Change of applicant information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |